TrialClinical pharmacokinetics2016

Pharmacokinetics, Safety and Tolerability of ABT-494, a Novel Selective JAK 1 Inhibitor, in Healthy Volunteers and Subjects with Rheumatoid Arthritis.

Mohamed-Eslam F Mohamed et al.PubMed ↗Publisher ↗

No numbers read from the abstract.